帯状疱疹ワクチンの市場規模、シェア、成長分析、製品別、ワクチンの種類別、地域別 - 産業別予測、2024～2031年

帯状疱疹ワクチンの世界市場規模は、2022年に39億9,000万米ドルと評価され、2023年の42億9,000万米ドルから2031年には77億1,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは7.6％で成長する見通しです。

帯状疱疹ワクチン市場は、主に60歳以上の高齢者における帯状疱疹リスクの増加と先進国全体のヘルスケア政策の進展により、大きな成長を遂げています。CDCの報告によると、米国人の約3人に1人が生涯のうちに帯状疱疹を発症するとされており、米国、カナダ、英国、ドイツなどの国々ではワクチン接種が強く推奨され、特にCOVID-19の大流行時にはその傾向が強まりました。コストが高いにもかかわらず、革新的な組み換えワクチンへのシフトが市場の見通しに拍車をかけています。CDCが2018年、ゾスタバックスよりもシングリックスを優先したことは、この動向を浮き彫りにしています。高齢化に伴い帯状疱疹患者の増加が予想される中、予防手段としての帯状疱疹ワクチン接種の重要性がますます認識されるようになり、さらなる採用と市場成長の原動力となっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2023年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術の進歩
• 規制情勢
• ケーススタディ

帯状疱疹ワクチン市場規模：製品別

• 市場概要
• シングリックス
• ゾスタバックス
• スカイゾスター

帯状疱疹ワクチン市場規模：ワクチンの種類別

• 市場概要
• 組み換えワクチン
• 生弱毒化ワクチン

帯状疱疹ワクチン市場規模：地域別

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2023年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2021-2023）

主要企業プロファイル

• GlaxoSmithKline（GSK）
• Merck & Co., Inc.
• Pfizer Inc.
• BioNTech SE
• SK bioscience
• GeneOne Life Science
• Curevo Inc.
• Vaccitech
• Jiangsu Recbio Technology Co., Ltd.
• Changchun BCHT Biotechnology Co.

結論と推奨事項

Global Shingles Vaccine Market size was valued at USD 3.99 billion in 2022 and is poised to grow from USD 4.29 billion in 2023 to USD 7.71 billion by 2031, growing at a CAGR of 7.6% during the forecast period (2024-2031).

The shingles vaccine market is experiencing significant growth, primarily driven by the increased shingles risk among individuals aged 60 and older and advancements in healthcare policies across developed countries. The CDC reports that around one in three Americans will develop shingles in their lifetime, prompting strong vaccination endorsements in countries like the U.S., Canada, the U.K., and Germany, particularly heightened during the COVID-19 pandemic. The shift towards innovative recombinant vaccines, despite their higher costs, is fueling market prospects. The CDC's 2018 preference for Shingrix over Zostavax highlights this trend. With herpes zoster cases expected to rise with aging populations, the importance of shingles vaccination as a preventive measure is becoming increasingly recognized, driving further adoption and market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Shingles Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Shingles Vaccine Market Segmental Analysis

Global Shingles Vaccine Market is segmented by product, vaccine type and region. Based on product, the market is segmented into shingrix, zostavax and skyzoster. Based on vaccine type, the market is segmented into recombinant vaccine and live attenuated vaccine. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Shingles Vaccine Market

One of the primary drivers of the global shingles vaccine market is the escalating prevalence of shingles worldwide. This trend is largely attributed to the expanding aging population, which faces a heightened risk of developing shingles and experiencing associated complications. As more individuals reach an age where they are vulnerable to this viral infection, the demand for effective preventive measures grows significantly. Consequently, healthcare providers and patients alike are increasingly recognizing the importance of vaccination, thereby fueling market expansion and emphasizing the need for innovative solutions to mitigate this health concern on a global scale.

Restraints in the Global Shingles Vaccine Market

The Global Shingles Vaccine market faces significant restraints, primarily due to limited vaccine uptake in certain areas. While health authorities strongly advocate vaccination, actual participation is hindered by various factors. These include a lack of awareness about the vaccine's benefits, vaccine hesitancy among potential recipients, and apprehensions regarding possible side effects. These barriers collectively impede the market's expansion and prevent it from reaching its full potential, underscoring the necessity for enhanced educational efforts and outreach programs to address these concerns and improve vaccination rates in the affected regions.

Market Trends of the Global Shingles Vaccine Market

The Global Shingles Vaccine market is experiencing a notable upward trend, primarily fueled by the rising incidence of shingles, particularly among the aging population. As the demographic landscape shifts towards an older average age, the prevalence of herpes zoster infections is surging, prompting an urgent need for effective vaccination solutions. This growing awareness of shingles' potential complications and the effectiveness of available vaccines are further propelling market demand. Additionally, public health initiatives and recommendations from healthcare authorities aimed at increasing vaccination rates are expected to amplify growth, solidifying the shingles vaccine market's pivotal role in preventive healthcare strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Shingles Vaccine Market Size by Product & CAGR (2024-2031)

• Market Overview
• Shingrix
• Zostavax
• Skyzoster

Global Shingles Vaccine Market Size by Vaccine Type & CAGR (2024-2031)

• Market Overview
• Recombinant Vaccine
• Live Attenuated Vaccine

Global Shingles Vaccine Market Size & CAGR (2024-2031)

• North America (Product, Vaccine Type)
  • USA
  • Canada
• Europe (Product, Vaccine Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Vaccine Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Vaccine Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Vaccine Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• GlaxoSmithKline (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SK bioscience
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneOne Life Science
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curevo Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaccitech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Recbio Technology Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Changchun BCHT Biotechnology Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations